Document Detail

NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats.
MedLine Citation:
PMID:  16423620     Owner:  NLM     Status:  MEDLINE    
The synthetic compound NO-1886 (ibrolipim, [4-(4-bromo-2-cyano-phenylcarbamoyl)-benzyl]-phosphonic acid diethyl ester, CAS 133208-93-2) is a lipoprotein lipase (LPL)-promoting agent that decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels, and prevents fat accumulation in high fat-fed rats. However, the effect of NO-1886 on body weight, fat accumulation, and energy expenditure in ovariectomized (OVX) rats is not clear. The primary aim of this study was to ascertain whether NO-1886 ameliorated obesity in OVX rats and to examine the effects on fatty acid oxidation-related enzymes. NO-1886 decreased accumulation of visceral fat and suppressed the increase in body weight resulting from the ovariectomy. NO-1886 decreased the respiratory quotient and increased expression of the fatty acid translocase messenger RNA (mRNA) in the liver, soleus muscle, and mesenteric fat. NO-1886 also increased the expression of fatty acid-binding protein mRNA in the liver and soleus muscle and the expression of the uncoupling protein 3 (UCP3) mRNA in the heart, soleus muscle, and mesenteric fat, but not in the brown adipose tissue. Furthermore, NO-1886 did not affect UCP1 and UCP2 in brown adipose tissue. Therefore, amelioration of obesity by NO-1886 in OVX rats is possibly because of an the increased expression of fatty acid oxidation-related enzymes and UCP3, both of which are related to fatty acid transfer and fat use. Our study indicates that the LPL-promoting agent NO-1886 may be potentially beneficial in the treatment of obesity and obesity-linked health problems in postmenopausal women.
Seiichiro Kano; Masako Doi
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Metabolism: clinical and experimental     Volume:  55     ISSN:  0026-0495     ISO Abbreviation:  Metab. Clin. Exp.     Publication Date:  2006 Feb 
Date Detail:
Created Date:  2006-01-20     Completed Date:  2006-03-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375267     Medline TA:  Metabolism     Country:  United States    
Other Details:
Languages:  eng     Pagination:  151-8     Citation Subset:  IM    
Department of Pharmacology, Hokkaido College of Pharmacy, Hokkaido 047-0264, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adipose Tissue, Brown / drug effects,  metabolism
Antilipemic Agents / pharmacology*
Benzamides / pharmacology*
Blood Glucose / drug effects,  metabolism
Body Weight / drug effects
Carrier Proteins / biosynthesis*,  genetics*,  metabolism
Eating / drug effects
Fatty Acid Transport Proteins / biosynthesis,  genetics
Fatty Acid-Binding Proteins / biosynthesis,  genetics
Gene Expression / drug effects
Insulin / blood
Ion Channels
Leptin / blood
Mitochondrial Proteins
Muscle, Skeletal / metabolism
Myocardium / metabolism
Obesity / blood,  drug therapy*,  metabolism*
Organophosphorus Compounds / pharmacology*
Oxygen Consumption / drug effects
Proton-Translocating ATPases / biosynthesis,  genetics
RNA, Messenger / biosynthesis*,  chemistry,  genetics
Random Allocation
Reverse Transcriptase Polymerase Chain Reaction
Reg. No./Substance:
0/Antilipemic Agents; 0/Benzamides; 0/Blood Glucose; 0/Carrier Proteins; 0/Fatty Acid Transport Proteins; 0/Fatty Acid-Binding Proteins; 0/Ion Channels; 0/Leptin; 0/Mitochondrial Proteins; 0/Organophosphorus Compounds; 0/RNA, Messenger; 0/mitochondrial uncoupling protein 3; 11061-68-0/Insulin; 133208-93-2/4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide; EC ATPases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Insulin resistance in hypertension quantified by oral glucose tolerance test: comparison of methods.
Next Document:  Ascorbic acid and alpha-tocopherol down-regulate apolipoprotein A-I gene expression in HepG2 and Cac...